Navigation Links
ACRES and PharmaTrain Announce Strategic Alliance
Date:9/30/2013

Cambridge, Massachusetts (PRWEB) September 30, 2013

The Alliance for Clinical Research Excellence and Safety (ACRES) and PharmaTrain Federation, an international not-for-profit organisation for improving education and training of professionals in medicines development, today announced their creation of a Strategic Alliance to promote the adoption of new and reliable global standards for high-quality postgraduate education and training for individuals pursuing careers in the process of discovery, development, regulation and marketing of new medicines.

According to Dr. Greg Koski, President of ACRES and Dr. Ingrid Klingmann, Coordinator of PharmaTrain, the goal of the partnership is to develop and implement a systems approach to addressing the many challenges currently facing the global drug development and health-related research endeavor. Proposed projects include the development and dissemination of curriculum standards for educational programs and the implementation of a global quality assessment and recognition process for educational programmes and training courses as part of the shared infrastructure necessary for the multi-stakeholder integration of education in medicines development.

"There is nothing comparable to PharmaTrain," noted ACRES President and CEO, Dr. Greg Koski. "Since its inception, PharmaTrain has defined 180 content topics in its comprehensive Syllabus of Medicines Development and mapped them to 60 critical learning outcomes, which are aligned with the core competencies for scientists involved in medicines development. This rigorous approach to standards-based education and training has been missing in preparing professionals in medicines development. Our strategic alliance with PharmaTrain will facilitate the adoption and implementation of these standards worldwide with significant beneficial impact for the industry and for patients."

"PharmaTrain emerged as an education and training project within the
European Innovative Medicines Initiative --it is now ready to undertake the next step for globalisation," said PharmaTrain’s founding father, Fritz Bühler, Professor of Pharmaceutical Medicine and Cardiology at the University of Basel and former Head of Global Clinical Research and Development at Roche.

"To train a new generation of professionals in medicines development, a rigorous standardized but flexible curriculum is essential," said Dr. Ingrid Klingmann, who in addition to her leadership role at PharmaTrain is also Chairman of the Board of the European Forum for Good Clinical Practice (EFGCP). "Currently over 30 leading universities in Europe and North America have implemented the PharmaTrain curriculum-- with ACRES, our new strategic partner, we intend to offer PharmaTrain to the world."

Dr. Honorio Silva, ACRES Vice-President for System Integration and Professionalism, a long time proponent of outcome-based education for both academia and pharmaceuticals added, "This alliance is a major step toward achieving true professionalism in medicines development and clinical research. The strategic alliance between PharmaTrain and ACRES will catalyze the education and training of competent professionals according to uniform standards worldwide."

About ACRES    

ACRES, a global non-profit organization working in the public interest and based in Cambridge, Massachusetts, is building a comprehensive, sustainable and shareable system for clinical research worldwide. By bringing together experts, stakeholders, and like-minded organizations, ACRES’s goal is to collaboratively create and implement systems solutions that enhance safety, data quality and integrity, and operational excellence in an efficient and cost effective manner to improve the health and lives of people everywhere.

About PharmaTrain    

PharmaTrain Federation is the successor organization of the PharmaTrain project, which was developed within the European Innovative Medicines Initiative, a collaboration between the European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and the largest ever public-private partnership in biomedicine. PharmaTrain standardises and grows job-defined and competence-based training products in medicines development from a nucleus of 45 accredited University Centres of Excellence around the world in partnership with universities, pharmaceutical industry, regulatory agencies and standard setting societies.

Read the full story at http://www.prweb.com/releases/GregKoskiACRES/biomedicalresearch/prweb11139483.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ACRES Announces Strategic Alliance with Atlantis Global Research Institute
2. ACRES Launches Global Clinical Research Network Technology Platform
3. China Cord Blood Corporation Announces Resignation of Director
4. New AC Temperature Controller Announced by Xinmeiya Technology
5. Sigma-Aldrich Corporation Delcares Quarterly Dividend Of $0.215 Per Share And Announces Election Of New Vice President And Treasurer
6. SoundConnect Announces Comprehensive Next-Generation Unified Communication & Collaboration Hosted Services
7. TeselaGen Announces 1st Public Release of Computer-Aided DNA Design Software
8. Pittcon 2014 Announces Short Course Program
9. Hurel Corporation Announces Grant Program Based On Its 3-D Tissue Construct Technologies, Readies Call For Research Proposals From Academic Community
10. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
11. Pipette.com Announces Promotional T-Shirt and Other Specials for Neuroscience 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):